| Company Name | Sanofi |
|---|---|
| Protocol Number | OBS17337 |
| Title of Study | Observational study of atopic dermatitis patients treated with dupilumab in Taiwan |
| Primary Objective | To characterize the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment for adult AD patients, who are eligible for dupilumab reimbursement in Taiwan (e.g., used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching) |
| Number of Sites | 6 |
| Period of Study | From：2022 Jun to：2024 Jul |
| Number of Patients | 80人 |
| IRB Approval Date | NTUH: 15Jun2022 CGMH_LK: 13Jun2022 TPVGH: 21Jun2022 MMH: 28Jul2022 NTUH-HC: 11Jul2022 CSMUH: 16Aug2022 |
| Publication Plan / Date | 2024 Sep |
